NCT05230810 2026-03-16
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Criterium, Inc.
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT06595563 2026-02-19
ZEPHIR-02
Jules Bordet Institute
Phase 2 Recruiting
NCT06551116 2025-09-05
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine
Recruiting
NCT03417544 2025-04-02
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06305702 2024-03-12
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
Liaoning Cancer Hospital & Institute
Completed
NCT06278870 2024-02-26
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT05042791 2024-02-09
A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases
Jiangxi Provincial Cancer Hospital
Phase 2 Unknown
NCT04778982 2023-07-17
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Terminated
NCT05188495 2022-01-12
HELP
Peking University Cancer Hospital & Institute
Unknown
NCT04385563 2020-05-13
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown